Innovative vaccine approaches-a Keystone Symposia report
© 2022 New York Academy of Sciences..
The rapid development of COVID-19 vaccines was the result of decades of research to establish flexible vaccine platforms and understand pathogens with pandemic potential, as well as several novel changes to the vaccine discovery and development processes that partnered industry and governments. And while vaccines offer the potential to drastically improve global health, low-and-middle-income countries around the world often experience reduced access to vaccines and reduced vaccine efficacy. Addressing these issues will require novel vaccine approaches and platforms, deeper insight how vaccines mediate protection, and innovative trial designs and models. On June 28-30, 2021, experts in vaccine research, development, manufacturing, and deployment met virtually for the Keystone eSymposium "Innovative Vaccine Approaches" to discuss advances in vaccine research and development.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:1511 |
|---|---|
| Enthalten in: |
Annals of the New York Academy of Sciences - 1511(2022), 1 vom: 01. Mai, Seite 59-86 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
COVID-19 |
|---|
| Anmerkungen: |
Date Completed 19.05.2022 Date Revised 30.06.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/nyas.14739 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM335641687 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM335641687 | ||
| 003 | DE-627 | ||
| 005 | 20231225230319.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/nyas.14739 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1118.xml |
| 035 | |a (DE-627)NLM335641687 | ||
| 035 | |a (NLM)35029310 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cable, Jennifer |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Innovative vaccine approaches-a Keystone Symposia report |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 19.05.2022 | ||
| 500 | |a Date Revised 30.06.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2022 New York Academy of Sciences. | ||
| 520 | |a The rapid development of COVID-19 vaccines was the result of decades of research to establish flexible vaccine platforms and understand pathogens with pandemic potential, as well as several novel changes to the vaccine discovery and development processes that partnered industry and governments. And while vaccines offer the potential to drastically improve global health, low-and-middle-income countries around the world often experience reduced access to vaccines and reduced vaccine efficacy. Addressing these issues will require novel vaccine approaches and platforms, deeper insight how vaccines mediate protection, and innovative trial designs and models. On June 28-30, 2021, experts in vaccine research, development, manufacturing, and deployment met virtually for the Keystone eSymposium "Innovative Vaccine Approaches" to discuss advances in vaccine research and development | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a correlates of protection | |
| 650 | 4 | |a human challenge studies | |
| 650 | 4 | |a influenza | |
| 650 | 4 | |a pneumococcal disease | |
| 650 | 4 | |a streptococcus | |
| 650 | 4 | |a vaccine equity | |
| 650 | 4 | |a vaccines | |
| 650 | 7 | |a COVID-19 Vaccines |2 NLM | |
| 650 | 7 | |a Influenza Vaccines |2 NLM | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 700 | 1 | |a Rappuoli, Rino |e verfasserin |4 aut | |
| 700 | 1 | |a Klemm, Elizabeth J |e verfasserin |4 aut | |
| 700 | 1 | |a Kang, Gagandeep |e verfasserin |4 aut | |
| 700 | 1 | |a Mutreja, Ankur |e verfasserin |4 aut | |
| 700 | 1 | |a Wright, Gavin J |e verfasserin |4 aut | |
| 700 | 1 | |a Pizza, Mariagrazia |e verfasserin |4 aut | |
| 700 | 1 | |a Castro, Sowmya Ajay |e verfasserin |4 aut | |
| 700 | 1 | |a Hoffmann, Joseph P |e verfasserin |4 aut | |
| 700 | 1 | |a Alter, Galit |e verfasserin |4 aut | |
| 700 | 1 | |a Carfi, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Pollard, Andrew J |e verfasserin |4 aut | |
| 700 | 1 | |a Krammer, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Gupta, Ravindra K |e verfasserin |4 aut | |
| 700 | 1 | |a Wagner, Caroline E |e verfasserin |4 aut | |
| 700 | 1 | |a Machado, Viviane |e verfasserin |4 aut | |
| 700 | 1 | |a Modjarrad, Kayvon |e verfasserin |4 aut | |
| 700 | 1 | |a Corey, Lawrence |e verfasserin |4 aut | |
| 700 | 1 | |a B Gilbert, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Dougan, Gordon |e verfasserin |4 aut | |
| 700 | 1 | |a Lurie, Nicole |e verfasserin |4 aut | |
| 700 | 1 | |a Bjorkman, Pamela J |e verfasserin |4 aut | |
| 700 | 1 | |a Chiu, Christopher |e verfasserin |4 aut | |
| 700 | 1 | |a Nemes, Elisa |e verfasserin |4 aut | |
| 700 | 1 | |a Gordon, Stephen B |e verfasserin |4 aut | |
| 700 | 1 | |a Steer, Andrew C |e verfasserin |4 aut | |
| 700 | 1 | |a Rudel, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Blish, Catherine A |e verfasserin |4 aut | |
| 700 | 1 | |a Sandberg, John Tyler |e verfasserin |4 aut | |
| 700 | 1 | |a Brennan, Kiva |e verfasserin |4 aut | |
| 700 | 1 | |a Klugman, Keith P |e verfasserin |4 aut | |
| 700 | 1 | |a Stuart, Lynda M |e verfasserin |4 aut | |
| 700 | 1 | |a Madhi, Shabir A |e verfasserin |4 aut | |
| 700 | 1 | |a Karp, Christopher L |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of the New York Academy of Sciences |d 1945 |g 1511(2022), 1 vom: 01. Mai, Seite 59-86 |w (DE-627)NLM000012823 |x 1749-6632 |7 nnns |
| 773 | 1 | 8 | |g volume:1511 |g year:2022 |g number:1 |g day:01 |g month:05 |g pages:59-86 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/nyas.14739 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 1511 |j 2022 |e 1 |b 01 |c 05 |h 59-86 | ||